{"entity":{"id":"normunity","kind":"company","name":"Normunity","aka":["Normunity AccelCo, Inc."],"tldr":"Normunity develops antibody medicines that direct the immune system's T cells against tumours. Its lead, NRM-823, recognises a target found on several solid tumours but not on normal tissue, and is in an early trial.","summary":"Normunity, located in Boston, Massachusetts, and New Haven, Connecticut, creates anti-cancer therapies at the interface of the immune system and the tumour, built on research by scientific founder Lieping Chen at Yale School of Medicine; Rachel Humphrey was founding chief executive. It announced a USD 65 million Series A in October 2022, led by Canaan with Sanofi Ventures, Taiho Ventures and Osage University Partners, and a USD 75 million Series B in January 2025, co-led by Samsara BioCapital and Enavate Sciences with Regeneron Ventures, Pfizer Ventures and YK Bioventures. Its lead, NRM-823, is a first-in-class T cell engager against what the company describes as a novel, highly tumour-specific target absent in normal systemic tissues; the first patient was dosed in November 2025 in a phase 1a/1b study (NCT07182149) alone and with checkpoint inhibition in head and neck, oesophageal, gastric and gastro-oesophageal junction cancers. Its first registered cancer trial, NCT07182149, was posted on ClinicalTrials.gov in September 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://normunity.com/"},{"label":"Series B release, January 2025","url":"https://normunity.com/normunity-closes-75-million-series-b-financing-to-advance-lead-drug-program-into-the-clinic-and-broaden-pipeline-of-novel-anti-cancer-therapies-targeting-untapped-drug-mechanisms/"},{"label":"First patient dosed with NRM-823, November 2025","url":"https://normunity.com/normunity-announces-first-patient-dosed-in-phase-1-clinical-study-of-nrm-823-a-t-cell-engager-against-a-novel-tumor-specific-target-in-patients-with-solid-tumors/"},{"label":"ClinicalTrials.gov: phase 1a/1b trial of NRM-823 (NCT07182149)","url":"https://clinicaltrials.gov/study/NCT07182149"}],"tags":[],"related":[],"cancers":["head-and-neck","oesophageal-squamous-cell-carcinoma","oesophageal-adenocarcinoma","gastric"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read.","The NRM-823 target is not disclosed.","The registry sponsor is Normunity AccelCo, Inc.; its relationship to Normunity is assumed from the shared name and programme.","Company news and financing releases read on 29 October 2026."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://normunity.com/","stage":"growth","investors":["samsara-biocapital","pfizer-ventures","sanofi-ventures"],"funding":[{"round":"Series A","year":2022,"amountUsd":65000000,"source":"https://normunity.com/normunity-announces-65-million-series-a-financing-to-expand-the-frontier-of-precision-immuno-oncology-with-immune-normalizer-therapies/","note":"Led by Canaan, with Sanofi Ventures, Taiho Ventures and Osage University Partners."},{"round":"Series B","year":2025,"amountUsd":75000000,"source":"https://normunity.com/normunity-closes-75-million-series-b-financing-to-advance-lead-drug-program-into-the-clinic-and-broaden-pipeline-of-novel-anti-cancer-therapies-targeting-untapped-drug-mechanisms/","note":"Co-led by Samsara BioCapital and Enavate Sciences."}]},"route":"/companies/normunity/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"oesophageal-adenocarcinoma","kind":"cancer","name":"Oesophageal and junctional adenocarcinoma","route":"/cancers/oesophageal-adenocarcinoma/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"company":[{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/"},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/"},{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/"}]}}